This video has been solely funded by a grant from BTG Pharmaceuticals (a SERB company). BTG were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by OmniaMed Communications.
Healthcare professionals involved in the management of patients with atrial fibrillation and/or congestive heart failure are invited to watch our video where our expert speakers discuss the place of digoxin in current clinical practice, the most relevant clinical trial evidence to support its use and its mechanism of action. Additionally, they will detail the mechanism of digoxin toxicity and how to assess and manage it appropriately.
